Phenylacetyl-coenzyme A (CoA) is a key intermediate in aerobic catabolism of phenylacetate in bacteria such asPseudomonas, when cultured in minimal media using phenylacetate as the sole carbon source.1It is a precursor in the synthesis of the antibiotic penicillin G found in industrial strains ofP. chrysogenum. Phenylacetyl-CoA also acts as an effector molecule of the TetR family transcriptional repressor PaaR inT. thermophilusand the GntR family transcriptional regulator PaaX inE. coliandPseudomonas, binding to each protein to induce derepression of various genes.2
Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.